Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Friday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald upped their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an overweight rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Price Performance

VNDA opened at $5.02 on Friday. The stock has a 50-day moving average price of $5.52 and a 200-day moving average price of $5.09. The firm has a market cap of $292.62 million, a PE ratio of -63.75 and a beta of 0.77. Vanda Pharmaceuticals has a 1 year low of $3.30 and a 1 year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. The business had revenue of $50.47 million during the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. As a group, sell-side analysts anticipate that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SageView Advisory Group LLC bought a new stake in Vanda Pharmaceuticals during the 1st quarter worth approximately $34,000. Meeder Asset Management Inc. purchased a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $39,000. China Universal Asset Management Co. Ltd. grew its holdings in Vanda Pharmaceuticals by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 4,387 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $61,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in Vanda Pharmaceuticals by 18.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 2,425 shares in the last quarter. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.